Homepage > Company > Media > Pharma News > 2022 > Generic Version of Sanofi-Aventis’ Multaq Gets Tentative Approval

Generic Version of Sanofi-Aventis’ Multaq Gets Tentative Approval

Alembic Pharmaceuticals has gotten tentative approval for its abbreviated new drug application (ANDA) for dronedarone, a generic equivalent to Sanofi-Aventis’ anti-arrhythmic Multaq, which the FDA approved in 2009.

Dronedarone is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.

Tentative ANDA approvals are issued for generics that meet the substantive requirements for approval, but the drug product may not be marketed until the ANDA gains final agency approval.

January 12, 2022

https://www.fdanews.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.